Furanodiene is primarily studied for its potential anticancer properties. It has shown inhibitory effects on the growth of various cancer cell lines, including breast, liver, and colon cancers, by inducing apoptosis and cell cycle arrest. Research indicates it may suppress tumor progression through modulation of signaling pathways such as NF-κB and MAPK. Additionally, furanodiene exhibits anti-inflammatory and antimicrobial activities, making it a candidate for development in pharmaceuticals. It is also investigated for use in combination therapies to enhance the efficacy of conventional chemotherapeutic agents. Most studies remain in the preclinical stage, focusing on its bioavailability and mechanism of action.